Table 3 Mean ± standard deviation VASI score for vitiligo type and lesion location at 3 months after the start of treatment compared among the placebo, monotherapy, and combination therapy groups (ITT analysis).

From: The efficacy of bimatoprost ophthalmic solution combined with NB-UVB phototherapy in non-segmental and segmental vitiligo: a single-blind randomized controlled study

Type and location

n

Placebo

Bimatoprost 0.01% monotherapy

Bimatoprost 0.01% + NBUVB

p*

Type of vitiligo

 Non-segmental type

13

97.69 ± 4.4

83.46 ± 22.8

76.92 ± 17.3

0.013b

 Segmental type

6

94.17 ± 10.2

88.33 ± 11.3

79.17 ± 26.5

0.357

Location of lesion

 Face and neck

8

91.88 ± 8.4

79.38 ± 23.5

79.37 ± 14.0

0.308

 Other areas

11

100.00 ± 0.0

89.09 ± 16.3

76.36 ± 23.9

0.008b

  1. A p-value < 0.05 indicates statistical significance.
  2. VASI score Vitiligo Area Scoring Index score, NBUVB narrowband ultraviolet B phototherapy, ITT intention to treat.
  3. *Repeated measures analysis of variance (ANOVA) with multiple comparisons by Bonferroni method.
  4. aPlacebo vs. monotherapy.
  5. bPlacebo vs. combination therapy.
Back to article page